Selected research
Industry Research
End Stage Renal Disease Industry Research Report 2026
Market perspective
The global End Stage Renal Disease market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the End Stage Renal Disease market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the End Stage Renal Disease market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the End Stage Renal Disease market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of End Stage Renal Disease include Newsol, Baxter, Guangdong Biolight, B. Braun, DaVita, Fresenius, Jafron Biomedical, Medtronic and Mayo Clinic, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global End Stage Renal Disease market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to End Stage Renal Disease.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
End Stage Renal Disease Market by Company
Newsol
Baxter
Guangdong Biolight
B. Braun
DaVita
Fresenius
Jafron Biomedical
Medtronic
Mayo Clinic
Nipro
Nikkiso
Sanxin Medtec
SWS Hemodialysis Care
Tianyi Medical
WEGO
Asahi Kasei
End Stage Renal Disease Segment by Type
Hemodialysis
Kidney Transplantation
Peritoneal Dialysis
End Stage Renal Disease Segment by Application
At Homes
Kidney Dialysis Centers
Hospitals
Others
End Stage Renal Disease Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global End Stage Renal Disease market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of End Stage Renal Disease and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of End Stage Renal Disease.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of End Stage Renal Disease companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Hemodialysis
- Kidney Transplantation
- Peritoneal Dialysis
Applications
- At Homes
- Kidney Dialysis Centers
- Hospitals
- Others
Companies covered
- Newsol
- Baxter
- Guangdong Biolight
- B. Braun
- DaVita
- Fresenius
- Jafron Biomedical
- Medtronic
- Mayo Clinic
- Nipro
- Nikkiso
- Sanxin Medtec
- SWS Hemodialysis Care
- Tianyi Medical
- WEGO
- Asahi Kasei
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 End Stage Renal Disease by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Hemodialysis
- 2.2.3 Kidney Transplantation
- 2.2.4 Peritoneal Dialysis
- 2.3 End Stage Renal Disease by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 At Homes
- 2.3.3 Kidney Dialysis Centers
- 2.3.4 Hospitals
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 End Stage Renal Disease Breakdown Data by Type
- 3.1 Global End Stage Renal Disease Historic Market Size by Type (2021-2026)
- 3.2 Global End Stage Renal Disease Forecasted Market Size by Type (2027-2032)
4 End Stage Renal Disease Breakdown Data by Application
- 4.1 Global End Stage Renal Disease Historic Market Size by Application (2021-2026)
- 4.2 Global End Stage Renal Disease Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global End Stage Renal Disease Market Perspective (2021-2032)
- 5.2 Global End Stage Renal Disease Growth Trends by Region
- 5.2.1 Global End Stage Renal Disease Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 End Stage Renal Disease Historic Market Size by Region (2021-2026)
- 5.2.3 End Stage Renal Disease Forecasted Market Size by Region (2027-2032)
- 5.3 End Stage Renal Disease Market Dynamics
- 5.3.1 End Stage Renal Disease Industry Trends
- 5.3.2 End Stage Renal Disease Market Drivers
- 5.3.3 End Stage Renal Disease Market Challenges
- 5.3.4 End Stage Renal Disease Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top End Stage Renal Disease Players by Revenue
- 6.1.1 Global Top End Stage Renal Disease Players by Revenue (2021-2026)
- 6.1.2 Global End Stage Renal Disease Revenue Market Share by Players (2021-2026)
- 6.2 Global End Stage Renal Disease Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of End Stage Renal Disease Head Office and Area Served
- 6.4 Global End Stage Renal Disease Players, Product Type & Application
- 6.5 Global End Stage Renal Disease Manufacturers Established Date
- 6.6 Global End Stage Renal Disease Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America End Stage Renal Disease Market Size (2021-2032)
- 7.2 North America End Stage Renal Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America End Stage Renal Disease Market Size by Country (2021-2026)
- 7.4 North America End Stage Renal Disease Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe End Stage Renal Disease Market Size (2021-2032)
- 8.2 Europe End Stage Renal Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe End Stage Renal Disease Market Size by Country (2021-2026)
- 8.4 Europe End Stage Renal Disease Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific End Stage Renal Disease Market Size (2021-2032)
- 9.2 Asia-Pacific End Stage Renal Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific End Stage Renal Disease Market Size by Country (2021-2026)
- 9.4 Asia-Pacific End Stage Renal Disease Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America End Stage Renal Disease Market Size (2021-2032)
- 10.2 South America End Stage Renal Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America End Stage Renal Disease Market Size by Country (2021-2026)
- 10.4 South America End Stage Renal Disease Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa End Stage Renal Disease Market Size (2021-2032)
- 11.2 Middle East & Africa End Stage Renal Disease Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa End Stage Renal Disease Market Size by Country (2021-2026)
- 11.4 Middle East & Africa End Stage Renal Disease Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Newsol
- 12.1.1 Newsol Company Information
- 12.1.2 Newsol Business Overview
- 12.1.3 Newsol Revenue in End Stage Renal Disease Business (2021-2026)
- 12.1.4 Newsol End Stage Renal Disease Product Portfolio
- 12.1.5 Newsol Recent Developments
- 12.2 Baxter
- 12.2.1 Baxter Company Information
- 12.2.2 Baxter Business Overview
- 12.2.3 Baxter Revenue in End Stage Renal Disease Business (2021-2026)
- 12.2.4 Baxter End Stage Renal Disease Product Portfolio
- 12.2.5 Baxter Recent Developments
- 12.3 Guangdong Biolight
- 12.3.1 Guangdong Biolight Company Information
- 12.3.2 Guangdong Biolight Business Overview
- 12.3.3 Guangdong Biolight Revenue in End Stage Renal Disease Business (2021-2026)
- 12.3.4 Guangdong Biolight End Stage Renal Disease Product Portfolio
- 12.3.5 Guangdong Biolight Recent Developments
- 12.4 B. Braun
- 12.4.1 B. Braun Company Information
- 12.4.2 B. Braun Business Overview
- 12.4.3 B. Braun Revenue in End Stage Renal Disease Business (2021-2026)
- 12.4.4 B. Braun End Stage Renal Disease Product Portfolio
- 12.4.5 B. Braun Recent Developments
- 12.5 DaVita
- 12.5.1 DaVita Company Information
- 12.5.2 DaVita Business Overview
- 12.5.3 DaVita Revenue in End Stage Renal Disease Business (2021-2026)
- 12.5.4 DaVita End Stage Renal Disease Product Portfolio
- 12.5.5 DaVita Recent Developments
- 12.6 Fresenius
- 12.6.1 Fresenius Company Information
- 12.6.2 Fresenius Business Overview
- 12.6.3 Fresenius Revenue in End Stage Renal Disease Business (2021-2026)
- 12.6.4 Fresenius End Stage Renal Disease Product Portfolio
- 12.6.5 Fresenius Recent Developments
- 12.7 Jafron Biomedical
- 12.7.1 Jafron Biomedical Company Information
- 12.7.2 Jafron Biomedical Business Overview
- 12.7.3 Jafron Biomedical Revenue in End Stage Renal Disease Business (2021-2026)
- 12.7.4 Jafron Biomedical End Stage Renal Disease Product Portfolio
- 12.7.5 Jafron Biomedical Recent Developments
- 12.8 Medtronic
- 12.8.1 Medtronic Company Information
- 12.8.2 Medtronic Business Overview
- 12.8.3 Medtronic Revenue in End Stage Renal Disease Business (2021-2026)
- 12.8.4 Medtronic End Stage Renal Disease Product Portfolio
- 12.8.5 Medtronic Recent Developments
- 12.9 Mayo Clinic
- 12.9.1 Mayo Clinic Company Information
- 12.9.2 Mayo Clinic Business Overview
- 12.9.3 Mayo Clinic Revenue in End Stage Renal Disease Business (2021-2026)
- 12.9.4 Mayo Clinic End Stage Renal Disease Product Portfolio
- 12.9.5 Mayo Clinic Recent Developments
- 12.10 Nipro
- 12.10.1 Nipro Company Information
- 12.10.2 Nipro Business Overview
- 12.10.3 Nipro Revenue in End Stage Renal Disease Business (2021-2026)
- 12.10.4 Nipro End Stage Renal Disease Product Portfolio
- 12.10.5 Nipro Recent Developments
- 12.11 Nikkiso
- 12.11.1 Nikkiso Company Information
- 12.11.2 Nikkiso Business Overview
- 12.11.3 Nikkiso Revenue in End Stage Renal Disease Business (2021-2026)
- 12.11.4 Nikkiso End Stage Renal Disease Product Portfolio
- 12.11.5 Nikkiso Recent Developments
- 12.12 Sanxin Medtec
- 12.12.1 Sanxin Medtec Company Information
- 12.12.2 Sanxin Medtec Business Overview
- 12.12.3 Sanxin Medtec Revenue in End Stage Renal Disease Business (2021-2026)
- 12.12.4 Sanxin Medtec End Stage Renal Disease Product Portfolio
- 12.12.5 Sanxin Medtec Recent Developments
- 12.13 SWS Hemodialysis Care
- 12.13.1 SWS Hemodialysis Care Company Information
- 12.13.2 SWS Hemodialysis Care Business Overview
- 12.13.3 SWS Hemodialysis Care Revenue in End Stage Renal Disease Business (2021-2026)
- 12.13.4 SWS Hemodialysis Care End Stage Renal Disease Product Portfolio
- 12.13.5 SWS Hemodialysis Care Recent Developments
- 12.14 Tianyi Medical
- 12.14.1 Tianyi Medical Company Information
- 12.14.2 Tianyi Medical Business Overview
- 12.14.3 Tianyi Medical Revenue in End Stage Renal Disease Business (2021-2026)
- 12.14.4 Tianyi Medical End Stage Renal Disease Product Portfolio
- 12.14.5 Tianyi Medical Recent Developments
- 12.15 WEGO
- 12.15.1 WEGO Company Information
- 12.15.2 WEGO Business Overview
- 12.15.3 WEGO Revenue in End Stage Renal Disease Business (2021-2026)
- 12.15.4 WEGO End Stage Renal Disease Product Portfolio
- 12.15.5 WEGO Recent Developments
- 12.16 Asahi Kasei
- 12.16.1 Asahi Kasei Company Information
- 12.16.2 Asahi Kasei Business Overview
- 12.16.3 Asahi Kasei Revenue in End Stage Renal Disease Business (2021-2026)
- 12.16.4 Asahi Kasei End Stage Renal Disease Product Portfolio
- 12.16.5 Asahi Kasei Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst